LEPU SCIENTECH MEDICAL TECHNOLOGY (SHANGHAI) CO., LTD.*

樂普心泰醫療科技(上海)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2291)

SUPPLEMENTAL NOTICE OF THE 2024 ANNUAL GENERAL MEETING

Reference is made to the notice dated April 17, 2025 (the "**Original AGM Notice**") in relation to the 2024 annual general meeting (the "**2024 AGM**") of LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.* (the "**Company**") to be held at 10:30 a.m. on Thursday, May 22, 2025 at Conference Room, 5/F, Building 41, No. 258, Xinzhuan Road, Songjiang District, Shanghai, the PRC and the resolutions to be proposed at the AGM for the Shareholders' approval. Unless otherwise specified, capitalized terms used in this supplemental notice shall have the same meanings as those defined in the supplemental circular of the Company dated May 6, 2025 (the "**Supplemental Circular**").

Details of resolutions Nos. 1 to 11 (inclusive) to be considered at the 2024 AGM are stated in the Original AGM Notice. Save for the additional resolution set out below, all information contained in the Original AGM Notice remains valid and unchanged.

SUPPLEMENTAL NOTICE IS HEREBY GIVEN THAT the 2024 AGM of the Company will be held as originally scheduled at 10:30 a.m. on Thursday, May 22, 2025 at Conference Room, 5/F, Building 41, No. 258, Xinzhuan Road, Songjiang District, Shanghai, the PRC to, among others, consider and, if thought fit, pass the following additional resolution.

SPECIAL RESOLUTION

(12) To consider and approve the granting of a general mandate to the Board to issue shares of the Company (the "**Shares**"):

"**THAT**:

(a) The Board be and is hereby granted, during the Relevant Period (as defined in paragraph (b) below), a general and unconditional mandate to issue, allot and/or deal with additional Shares (including any sale or transfer of treasury Shares), and to make or grant offers, agreements or options which would or might require the Shares to be issued, allotted and/or dealt with, subject to the following conditions:

(i) such mandate shall not extend beyond the Relevant Period save that the Board may during the Relevant Period make or grant offers, agreements or options which might require the exercise of such powers after the end of the Relevant Period;

(ii) the number of the Shares to be issued, allotted and/or deal with or agreed conditionally or unconditionally to be issued, allotted and/or dealt with by the Board shall not exceed 20% of its Shares (excluding any treasury Shares); and

(iii) the Board will only exercise its power under such mandate in accordance with the Company Law of the PRC and the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (as amended from time to time) or applicable laws, rules and regulations of other government or regulatory bodies and only if all necessary ratifications, approvals, or filings from the China Securities Regulatory Commission and/or other relevant PRC government authorities are obtained.

(b) For the purposes of this special resolution:

"**Relevant Period**" means the period from the passing of this special resolution until the earliest of:

(i) the conclusion of the next annual general meeting of the Company following the passing of this special resolution;

(ii) the expiration of the 12-month period following the passing of this special resolution; or

(iii) the date on which the authority granted to the Board as set out in this special resolution is revoked or varied by a special resolution of the shareholders of the Company in a general meeting.

(c) Contingent on the Board resolving to issue the Shares pursuant to paragraph (a) of this special resolution, the Board be authorized to increase the registered capital of the Company to reflect the number of such shares authorized to be issued by the Company pursuant to paragraph (a) of this special resolution and to make such appropriate and necessary amendments to the articles of association of the Company as they think fit to reflect such increases in the registered capital of the Company and to take any other action and complete any formality required to effect the issuance of the Shares pursuant to paragraph (a) of this special resolution and the increase in the registered capital of the Company."

Details of the above resolution submitted to the 2024 AGM are set out in the Supplemental Circular.

By Order of the Board
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.*
樂普心泰醫療科技(上海)股份有限公司
Ms. Chen Juan
Chairman of the Board and Executive Director

Shanghai, the People's Republic of China
May 6, 2025

As at the date of this notice, the Board comprises Ms. Chen Juan as an executive Director; Ms. Zhang Yuxin, Mr. Fu Shan and Mr. Zhu Guanfu as non-executive Directors; and Ms. Chan Ka Lai Vanessa, Mr. Zheng Yufeng, and Mr. Zheng Junwei as independent non-executive Directors.

* *The Company is a registered non-Hong Kong company as defined under the Companies Ordinance (Chapter 622 of the Laws of Hong Kong), and it is registered under its Chinese name and English name "LEPU ScienTech Medical Technology (Shanghai) Co., Ltd."*

Notes:

i. Save for the inclusion of the additional proposed resolution set out in this Supplemental AGM Notice (No. 12), there are no other changes to the Original AGM Notice. For details of resolutions Nos. 1 to 11 to be considered at the 2024 AGM, closure of the register of members of the Company, eligibility for attending the 2024 AGM, appointment of proxy and other relevant matters, please refer to the Original AGM Notice.

ii. Shareholders are advised to read the Circular issued by the Company on April 17, 2025 and the Supplemental Circular to the Shareholders issued on May 6, 2025 which contain detailed information concerning the resolutions to be considered at the 2024 AGM.

iii. The Second Proxy Form

(1) The new proxy form for the 2024 AGM (the "**Second Proxy Form**"), which supersedes the original proxy form for use at the 2024 AGM issued by the Company on April 17, 2025 (the "**Original Proxy Form**") and the revised proxy form for use at the 2024 AGM issued by the Company on April 23, 2025 (the "**Revised Proxy Form**"), has been prepared and is enclosed with this Supplemental AGM Notice.

(2) Whether or not you are able to attend the AGM, you are requested to complete the accompanying Second Proxy Form in accordance with the instructions printed thereon and return it to the Company's H Share Share Registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong as soon as possible but in any event not less than 24 hours before the time appointed for the holding of the 2024 AGM (i.e. not later than 10:30 a.m. on May 21, 2025) or the adjourned meeting (as the case may be) (the "**Closing Time**"). Completion and return of the form of proxy will not preclude the shareholders of the Company from attending and voting in person at the 2024 AGM or any adjournment thereof.

(3) Shareholder who has not yet lodged the Original Proxy Form and/or the Revised Proxy Form with the Company's H Share Registrar is requested to lodge the Second Proxy Form if he/she wishes to appoint a proxy to attend the 2024 AGM on his/her behalf. In this case, the Original Proxy Form and the Revised Proxy Form should not be lodged with the Company's H Share Registrar.

(4) Shareholder who has already lodged the Original Proxy Form and/or the Revised Proxy Form with the Company's H Share Registrar should note that:

(i) all Original Proxy Forms shall be deemed invalid. The Original Proxy Form will not be treated as a valid proxy form, even if properly completed and signed. The proxy appointed by the shareholder under the Original Proxy Form will not be entitled to vote at 2024 AGM. Shareholders who have already lodged the Original Proxy Form should duly complete and return the Second Proxy Form in accordance with the instructions printed thereon not less than 24 hours before the Closing Time.

(ii) the Second Proxy Form lodged with the Company's H Share Registrar before the Closing Time will revoke and supersede the Original Proxy Form and/or the Revised Proxy Form previously lodged by him/her. The Second Proxy Form will be treated as a valid form of proxy lodged by the shareholder if correctly completed; and

(iii) if no Second Proxy Form is lodged with the Company's H Share Registrar, or if lodged after the Closing Time, or if lodged before the Closing Time but is incorrectly completed, the Revised Proxy Form will remain valid and effective to the fullest extent applicable if correctly completed. The proxy appointed under the Revised Proxy Form will also be entitled to vote in accordance with the instructions previously given by the shareholder or at his/her discretion (if no such instructions are given) on any resolution properly put to the 2024 AGM including the new resolution No. 12 which was not set out in the Revised Proxy Form.